EA009620B1 - Производные 2,3,6-тризамещённого-4-пиримидона - Google Patents

Производные 2,3,6-тризамещённого-4-пиримидона Download PDF

Info

Publication number
EA009620B1
EA009620B1 EA200501516A EA200501516A EA009620B1 EA 009620 B1 EA009620 B1 EA 009620B1 EA 200501516 A EA200501516 A EA 200501516A EA 200501516 A EA200501516 A EA 200501516A EA 009620 B1 EA009620 B1 EA 009620B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
pyrimidin
group
piperazin
pyridyl
Prior art date
Application number
EA200501516A
Other languages
English (en)
Russian (ru)
Other versions
EA200501516A1 (ru
Inventor
Казутоси Ватанабе
Фумиаки Уехара
Синсуке Хики
Сатоси Йокосима
Йосихиро Усуи
Масахиро Окуяма
Ая Сода
Кейити Аритомо
Тосиюки Кохара
Кендзи Фукунага
Original Assignee
Мицубиси Фарма Корпорейшн
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мицубиси Фарма Корпорейшн, Санофи-Авентис filed Critical Мицубиси Фарма Корпорейшн
Publication of EA200501516A1 publication Critical patent/EA200501516A1/ru
Publication of EA009620B1 publication Critical patent/EA009620B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200501516A 2003-03-26 2004-03-26 Производные 2,3,6-тризамещённого-4-пиримидона EA009620B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003126022 2003-03-26
JP2003126021 2003-03-26
PCT/JP2004/004320 WO2004085408A1 (en) 2003-03-26 2004-03-26 2, 3, 6-trisubstituted-4-pyrimidone derivatives

Publications (2)

Publication Number Publication Date
EA200501516A1 EA200501516A1 (ru) 2006-04-28
EA009620B1 true EA009620B1 (ru) 2008-02-28

Family

ID=33100427

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501516A EA009620B1 (ru) 2003-03-26 2004-03-26 Производные 2,3,6-тризамещённого-4-пиримидона

Country Status (15)

Country Link
US (1) US7504411B2 (pt)
EP (3) EP2305651A1 (pt)
JP (1) JP4679509B2 (pt)
KR (1) KR100985419B1 (pt)
CN (1) CN1764650B (pt)
AR (1) AR045677A1 (pt)
AU (1) AU2004223987B2 (pt)
BR (1) BRPI0409042A (pt)
CA (1) CA2520027C (pt)
EA (1) EA009620B1 (pt)
IL (1) IL170877A (pt)
NO (1) NO20054952L (pt)
NZ (1) NZ543096A (pt)
TW (1) TWI357408B (pt)
WO (1) WO2004085408A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
AU2002337499B2 (en) 2001-09-21 2007-08-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
KR100754596B1 (ko) 2001-09-21 2007-09-05 미쯔비시 웰 파마 가부시키가이샤 3-치환-4-피리미돈 유도체
MXPA05006394A (es) * 2002-12-16 2007-04-16 Mitsubishi Pharma Corp Derivados de 4-pirimidona 3-sustituida.
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
PT1805164E (pt) * 2004-09-29 2011-04-11 Sanofi Aventis Derivados de 6-(piridinil)-4-pirimidona como inibidores de proteína-cinase tau 1
EP1802587A4 (en) * 2004-10-15 2010-02-17 Astrazeneca Ab SUBSTITUTED AMINO BINDINGS AND THEIR APPLICATIONS
WO2006041405A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
CN101115726A (zh) * 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
TW200740779A (en) * 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
US20100292205A1 (en) * 2006-08-23 2010-11-18 Pfizer Inc. Pyrimidone Compounds As GSK-3 Inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
EP2119709A4 (en) 2007-02-09 2011-08-17 Kaneka Corp PROCESS FOR PREPARING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8623873B2 (en) * 2007-06-28 2014-01-07 Intervet Inc. Substituted piperazines as CB1 antagonists
JP2010531360A (ja) * 2007-06-28 2010-09-24 インターベット インターナショナル ベー． フェー． Ｃｂ１拮抗剤としてのピペラジンの使用
AU2008297817A1 (en) 2007-09-14 2009-03-19 Mitsubishi Tanabe Pharma Corporation 6-pyrimidinyl-pyrimid-4-one derivative
WO2011019089A1 (en) * 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
WO2011019090A1 (en) 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
CN104211635A (zh) * 2013-06-03 2014-12-17 中国科学院上海药物研究所 一类哌啶类化合物及其制备方法、药物组合物和用途
US10246463B2 (en) 2015-04-07 2019-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hypoxia-inducible factor 1 (HIF-1) inhibitors
CN105130904B (zh) * 2015-08-24 2017-10-13 如东众意化工有限公司 一种2‑氰基‑4‑氯‑5‑（4‑甲基苯基）咪唑的合成方法
CN106854189A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种哌嗪化合物的合成方法
CN121843926A (zh) * 2023-06-16 2026-04-10 跨神经元治疗公司 5-ht2a受体调节剂及其使用方法
CN119841766B (zh) * 2025-01-16 2025-12-12 上海凌凯科技股份有限公司 一种戊二酰亚胺类化合物的制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
WO2003027080A1 (en) * 2001-09-21 2003-04-03 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US90490A (en) * 1869-05-25 Improved washing-machine
US187004A (en) * 1877-02-06 Improvement in water-wheels
JPS559099B2 (pt) 1972-08-07 1980-03-07
JPS4935633A (pt) 1972-08-09 1974-04-02
JPS4935632A (pt) 1972-08-10 1974-04-02
JPS5124008B2 (pt) 1972-08-10 1976-07-21
JPS5271481A (en) 1975-12-10 1977-06-14 Yoshitomi Pharmaceut Ind Ltd Synthesis of pyridylpyrimidines
JPS52139085A (en) 1976-05-13 1977-11-19 Hokuriku Pharmaceutical 22allylpiperazine derivative and method for its preparation
US4507302A (en) 1979-03-19 1985-03-26 The Upjohn Company Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
US4725600A (en) 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
EP0354179B1 (de) 1988-07-29 1994-08-17 Ciba-Geigy Ag Thiouracile als Stabilisatoren für chlorhaltige Polymerisate
ATE398176T1 (de) 1991-12-06 2008-07-15 Max Planck Gesellschaft Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit
DE4206145A1 (de) 1992-02-28 1993-09-02 Basf Ag Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja) 1992-07-03 2002-09-17 三菱化学株式会社 タウ蛋白質のリン酸化方法
JPH06329551A (ja) 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
AU733877C (en) 1996-12-05 2003-05-08 Amgen, Inc. Substituted pyrimidine compounds and their use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
IL130181A0 (en) 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
JP4064671B2 (ja) 2000-02-25 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
FR2806723B1 (fr) 2000-03-23 2002-05-10 Sanofi Synthelabo DERIVES D'ACIDE 8-OXO-5,8-DIHYDRO-6H-DIBENZO [a,g] QUINOLIZINE-13-PROPANOIQUE , LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2001070728A1 (en) 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
JP4653915B2 (ja) * 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
MXPA05006394A (es) 2002-12-16 2007-04-16 Mitsubishi Pharma Corp Derivados de 4-pirimidona 3-sustituida.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
WO2003027080A1 (en) * 2001-09-21 2003-04-03 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
CN1764650A (zh) 2006-04-26
US7504411B2 (en) 2009-03-17
EP2308854A1 (en) 2011-04-13
AR045677A1 (es) 2005-11-09
IL170877A (en) 2011-02-28
BRPI0409042A (pt) 2006-03-28
KR100985419B1 (ko) 2010-10-05
JP4679509B2 (ja) 2011-04-27
CN1764650B (zh) 2010-06-16
CA2520027A1 (en) 2004-10-07
WO2004085408A1 (en) 2004-10-07
HK1090368A1 (zh) 2006-12-22
AU2004223987A1 (en) 2004-10-07
CA2520027C (en) 2011-08-09
NO20054952L (no) 2005-10-25
JP2006521370A (ja) 2006-09-21
EP1608630A1 (en) 2005-12-28
TWI357408B (en) 2012-02-01
TW200510338A (en) 2005-03-16
US20060252768A1 (en) 2006-11-09
NZ543096A (en) 2008-07-31
EA200501516A1 (ru) 2006-04-28
AU2004223987B2 (en) 2010-02-18
KR20050111613A (ko) 2005-11-25
EP2305651A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
EA009620B1 (ru) Производные 2,3,6-тризамещённого-4-пиримидона
KR100881821B1 (ko) 3-치환-4-피리미돈 유도체
KR100754596B1 (ko) 3-치환-4-피리미돈 유도체
CN103524392B (zh) 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
US8188101B2 (en) Dihydropyridopyrimidines for the treatment of AB-related pathologies
JP6611358B2 (ja) 癌治療のためのｆａｓｎ阻害剤として有用なベンズアミド誘導体
HUT77941A (hu) Dihidropirimidinszármazékok és ezek alkalmazása
JP2014520858A (ja) タンキラーゼ阻害剤として用いるための新規な２−ピペリジン−１−イル−アセトアミド化合物
WO2021028806A1 (en) Heterocyclic wdr5 inhibitors as anti-cancer compounds
EA013839B1 (ru) Соединение 2-морфолино-4-пиримидона
EA014918B1 (ru) Замещенные бициклические пиримидоновые производные
JP4616003B2 (ja) ３−置換−４−ピリミドン誘導体
US20210284658A1 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
AU2003285777B2 (en) 3-substituted-4-pyrimidone derivatives
MXPA05010323A (en) 2, 3, 6-trisubstituted-4-pyrimidone derivatives
HK1090368B (en) 2,3,6-trisubstituted-4-pyrimidone derivatives
HK40048972A (en) Inhibitors of cyclin-dependent kinases

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU